Vernalis is a biotechnology and pharmaceutical company based in Cambridge, United Kingdom, specializing in the research, development, and commercialization of innovative medical products. The company focuses on candidates targeting oncology, neurodegeneration, anti-infectives, and inflammation, leveraging its expertise in fragment-based drug discovery, structural biology, and medicinal chemistry. Vernalis develops products through collaborations with various pharmaceutical companies and has a portfolio that includes treatments for cough-cold ailments, bacterial infections, and migraines. With a commitment to advancing its pipeline, Vernalis integrates its own research with commercial strategies to bring promising candidates to market. The company operates as a subsidiary of HitGen Inc. and Ligand Pharmaceuticals Incorporated, reflecting its collaborative approach in the pharmaceutical landscape.
Cita NeuroPharmaceuticals Inc. operates as a neuropharmaceutical company.
Ionix Pharmaceuticals
Acquisition in 2005
Ionix Pharmaceuticals, based in Cambridge UK, is a leader in the discovery and development of new analgesic medicines for the treatment of acute and chronic pain. Using proprietary drug targets and state-of-the-art chemistry, the company is developing medicines that are designed to alleviate pain associated with trauma, operative procedures, and debilitating diseases such as arthritis, diabetes and multiple sclerosis. Ionix Pharmaceuticals is a privately held company and was founded in 2001.
Pintex Pharmaceuticals, Inc. is a private pharmaceutical company located in Watertown, Massachusetts, dedicated to the discovery and development of structure-based cancer therapeutics. The company primarily focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a significant role in cancer progression. Founded in May 1999 by Dr. Kun Ping Lu, a Pew scholar at Harvard, along with Nobel laureate Dr. Walter Gilbert and Dr. Janusz Sowadski, Pintex was established to leverage years of research and patented discoveries from the Salk Institute for Biological Studies and Harvard University. The company's innovative approach aims to develop novel cancer therapeutics and diagnostics rooted in advanced scientific research.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.